Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Kulke

Showing results (91-100 of 182) with videos related to

Pageof 19
Sort By:
Carcinogenesis|January 8, 2011
Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma riskI-Chen Wu, Yang Zhao, Rihong Zhai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2010
Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinomaRihong Zhai, Feng Chen, Geoffrey Liu, et al.
Cancer|January 30, 2002
A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinomaDavid P Ryan, Matthew H Kulke, Charles S Fuchs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancerMatthew H Kulke, Lawrence S Blaszkowsky, David P Ryan, et al.
Endocrine-Related Cancer|April 11, 2013
A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumorsJ R Strosberg, J A Chan, D P Ryan, et al.
Neoplasia (New York, N.Y.)|April 8, 2011
Association between polymorphisms in cancer-related genes and early onset of esophageal adenocarcinomaI-Chen Wu, Yang Zhao, Rihong Zhai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2012
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumorsJennifer A Chan, Keith Stuart, Craig C Earle, et al.
International Journal of Cancer|March 17, 2012
Single nucleotide polymorphisms in the matrix metalloproteinase gene family and the frequency and duration of gastroesophageal reflux disease influence the risk of esophageal adenocarcinomaWinson Y Cheung, Rihong Zhai, Penny Bradbury, et al.
Endocrine-Related Cancer|January 16, 2013
Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional databaseMonica Ter-Minassian, Jennifer A Chan, Susanne M Hooshmand, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|March 24, 2009
p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal adenocarcinomaG Liu, D W Cescon, R Zhai, et al.
Pageof 19

Showing results (91-100 of 182) with videos related to

Sort By:
Pageof 19
Carcinogenesis|January 8, 2011
Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma riskI-Chen Wu, Yang Zhao, Rihong Zhai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2010
Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinomaRihong Zhai, Feng Chen, Geoffrey Liu, et al.
Cancer|January 30, 2002
A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinomaDavid P Ryan, Matthew H Kulke, Charles S Fuchs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancerMatthew H Kulke, Lawrence S Blaszkowsky, David P Ryan, et al.
Endocrine-Related Cancer|April 11, 2013
A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumorsJ R Strosberg, J A Chan, D P Ryan, et al.
Neoplasia (New York, N.Y.)|April 8, 2011
Association between polymorphisms in cancer-related genes and early onset of esophageal adenocarcinomaI-Chen Wu, Yang Zhao, Rihong Zhai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2012
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumorsJennifer A Chan, Keith Stuart, Craig C Earle, et al.
International Journal of Cancer|March 17, 2012
Single nucleotide polymorphisms in the matrix metalloproteinase gene family and the frequency and duration of gastroesophageal reflux disease influence the risk of esophageal adenocarcinomaWinson Y Cheung, Rihong Zhai, Penny Bradbury, et al.
Endocrine-Related Cancer|January 16, 2013
Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional databaseMonica Ter-Minassian, Jennifer A Chan, Susanne M Hooshmand, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|March 24, 2009
p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal adenocarcinomaG Liu, D W Cescon, R Zhai, et al.
Pageof 19